IP Library Granted Patent US 8,722,351
Granted Patent B2
US 8,722,351 · App. 13/496,418 · Granted May 13, 2014

Diagnostic tests for abnormal ovarian conditions

Inventors: Judith Luborsky (Riverside, IL); Seby Edassery (Skokie, IL)
Assignee: Rush University Medical Center
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,722,351
App. No.
13/496,418
Granted
May 13, 2014
Kind
B2
Abstract

Methods and compositions, and a kit for diagnosing ovarian disorders including autoimmunity and ovarian cancer. Ovarian autoimmunity is associated with unexplained infertility or idiopathic premature ovarian failure that occurs in the absence of polyglandular disease. Methods and composition described herein are used to detect ovarian autoimmunity before the onset of ovarian dysfunction. Thus, those individuals are identified who would benefit from therapy to maintain, as well as restore, ovarian function.

Claims (6)

1. A method to determine the presence and concentration of anti-SELENBP1 autoantibodies in a biological sample from an individual suspected of having ovarian cancer, comprises:

(a) contacting the biological sample with antigen SELENBP1 or a fragment thereof in conditions where naturally occurring autoantibodies form antigen antibody complexes with the antigen provided;

(b) determining the presence and concentration of anti-SELENBP1 autoantibodies in the biological sample by analysis of the complexes; and

(c) comparing the presence and concentration of anti-SELENBP1 autoantibodies determined in (b) with values in biological samples from subjects without ovarian cancer; and

(d) inferring that ovarian cancer is present in the individual, if anti-SELENBP1 autoantibodies are present in a concentration that is higher than the concentration in the subjects without ovarian cancer.

2. The method of claim 1 wherein SELENBP1 is a recombinant protein.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jun 30, 2015
From: RUSH UNIVERSITY MEDICAL CENTER
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 036040/0604 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 5, 2012
From: LUBORSKY, JUDITH; EDASSERY, SEBY
To: RUSH UNIVERSITY MEDICAL CENTER
Reel/Frame 028318/0086 →
Continuity (2)
Provisional Application 61243247 · Sep 17, 2009
Related Publication 20120252036A1 · Oct 4, 2012